Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 17, 2022 (5 years ago)

Moxifloxacin Ophthalmic Solution USP 0.5%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed impurities/degradation specifications

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Moxifloxacin Ophthalmic Solution USP 0.5%, 3 mL, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Dist. By Aurobindo Pharma USA, Inc. East Windsor, NJ 08520, NDC 72189-076-05

Affected NDC 72189-0076-05

Compare with the code on your package — it is the most precise check available.

Drug: Moxifloxacin Category: Eye Drops & Ophthalmic

Recalling firm
Direct Rx
NDC code
72189-076-05
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0637-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Moxifloxacin recalls

See all

Other recalls by Direct Rx

All 2022 recalls
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Direct Rx NDC 61919-482-30 D-0617-2026
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-0482-30 D-0568-2025
Class II · Moderate risk

Duloxetine D/R

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Direct Rx NDC 61919-422-30 D-0567-2025
Class II · Moderate risk

Ciprofloxacin Ophth Solution

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect Direct Rx NDC 61919-795-05 D-0364-2025